The price of Allarity Therapeutics Inc. (NASDAQ:ALLR) shares last traded on Wall Street rose 25.77% to $0.28.
Based on available information, 1 analysts follow Allarity Therapeutics Inc. (NASDAQ:ALLR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $8.00, we find $8.00. Given the previous closing price of $0.22, this indicates a potential upside of 3536.36 percent. ALLR stock price is now -41.86% away from the 50-day moving average and -78.43% away from the 200-day moving average. The market capitalization of the company currently stands at $4.11M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
.
A total of 13.38% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALLR stock. A new stake in Allarity Therapeutics Inc. shares was purchased by BARCLAYS PLC during the first quarter worth $4,000. In total, there are 13 active investors with 1.70% ownership of the company’s stock.
A candlestick chart of Allarity Therapeutics Inc. (NASDAQ: ALLR) showed a price of $0.2340 on Thursday morning. During the past 12 months, Allarity Therapeutics Inc. has had a low of $0.22 and a high of $12.86. As of last week, the company has a debt-to-equity ratio of 0.79, a current ratio of 0.50, and a quick ratio of 0.50. The fifty day moving average price for ALLR is $0.4760 and a two-hundred day moving average price translates $1.2830 for the stock.
The latest earnings results from Allarity Therapeutics Inc. (NASDAQ: ALLR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.52, missing analysts’ expectations of -$0.42 by -0.1. This compares to -$0.17 EPS in the same period last year. The company reported revenue of $4.56 million for the quarter, compared to $3.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.8 percent.
Allarity Therapeutics Inc.(ALLR) Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
